Circio Holding has successfully completed a private placement raising gross proceeds to the company of approx. NOK 200 ($21) million, through the allocation of 16,865,000 new shares. The Offer Price corresponds to a 9% discount to the volume weighted average share price (VWAP) quoted for trade in… Read More
Circio Holding and Avenue Biosciences have entered a research collaboration to combine their synergistic technologies to improve long-term expression of secreted proteins, relevant for treatment of a broad range of diseases. Secreting proteins from cells into surrounding tissue, or into circulation, opens new treatment opportunities beyond classical gene therapy for… Read More
Biotechnology companies Circio Holding and AaviGen have announced a research collaboration to develop heart disease gene therapies. The agreement will see the companies work to develop circVec-enhanced AAV vectors specifically engineered for targeted, low dose heart gene therapy. The collaboration focus will be on addressing genetic… Read More
Biotechnology companies Circio Holding and Acuitas Therapeutics have entered a technology evaluation agreement for an in vivo CAR-T cell therapy. As part of the agreement, Circio’s circVec circular RNA expression technology will be tested alongside Acuitas’ proprietary T-cell-targeted lipid nanoparticle (LNP) delivery system. The companies aim to assess whether Acuitas’ LNP technology can be deployed to deliver circVec for… Read More
Biotechnology company Circio Holding is set to collaborate with The University of Texas Medical Branch (UTMB) to evaluate treatments for infectious diseases. The partnership aims to design and test Circio’s circVEC technology for the prevention and treatment of infections, cancer and gene therapy. The technology allows for the long-term expression of proteins, protecting against… Read More
Circio Holding and NeoRegen Biotech have signed a second Material Transfer Agreement (MTA) to advance their ongoing collaboration for the delivery of circular RNA (circRNA) expression-based therapeutics. The collaboration now is progressing to the in vivo preclinical stage following successful proof-of-concept (POC) results from… Read More
Circular RNA technology continues to demonstrate broad capability to significantly boost protein expression level and durability for both viral and non-viral gene and cell therapy, according to new data. Circio Holding shared the new and strengthened in vivo data for its circVec platform at the… Read More
Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology. The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and… Read More
Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design. “The circVec 2.1 design is performing very well in… Read More
In vivo proof-of-concept for Circio Holding’s differentiated circVec platform approach to gene therapy has been demonstrated in two posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting. The in vivo data showed statistically significant higher expression level and durability for circVec… Read More
